Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age
- 1 February 2000
- Vol. 18 (15), 1456-1466
- https://doi.org/10.1016/s0264-410x(99)00423-5
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccineVaccine, 1996
- Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccineVaccine, 1996
- Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazideVaccine, 1995
- Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, ChileVaccine, 1995
- Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and CVaccine, 1992
- ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITISThe Lancet, 1983
- Immunologic Response of Man to Group B Meningococcal Polysaccharide VaccinesThe Journal of Infectious Diseases, 1972
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969
- HUMAN IMMUNITY TO THE MENINGOCOCCUSThe Journal of Experimental Medicine, 1969